Aoxin Q&M Dental Group Ltd. (SG:1D4) has released an update.
Aoxin Q&M Dental Group Ltd. reports on the strategic review of its associated company Acumen, following the expiration of its Laboratory Licence and the pending closure of the Sengkang Joint Testing and Vaccination Centre. Acumen’s profitability has been maintained by a government contract for COVID-19 vaccinations, despite financial losses in its non-COVID testing operations. The cessation of these operations highlights potential challenges for investors as the company navigates future business strategies.
For further insights into SG:1D4 stock, check out TipRanks’ Stock Analysis page.
